FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2186557382> ?p ?o ?g. }

• W2186557382 endingPage "61" @default.
• W2186557382 startingPage "49" @default.
• W2186557382 abstract "Lung cancer represents the leading cause of cancer mortality worldwide, accounting for ~1.2 million deaths each year. Improving survival in lung cancer is a major challenge for modern oncology considering that 5-year survival remains < 15%, across all stages of the disease with < 7% of patients alive 10 years after diagnosis. About 85% to 90% of lung cancers are non-small-cell lung cancer (NSCLC). Lung cancer is the leading cause of cancer-related mortality in Macedonia with more than 900 newly diagnosed lung cancer patients per year. The motive for undertaking the study was precisely the lack of adequate statistical data on treatment outcomes and survival rates of non-smal-cell lung cancer patients in the country. The main goal was to provide an assessment of progression-free survival and overall survival in NSCLC patients treated at UCRO-Skopje, over the past three years: 2009-2011. The research represents a follow-up study. The study was based on filling in forms for an epidemiological analysis of PFS and OS in NSCLC patients. These forms contain demographic, clinical and histological data, as well as dates of diagnosis, treatment initiation and outcomes. Data were collected from patient files for a period of three years (2009-2011), collected through the registration of each NSCLC patient treated in the period of the investigation. The statistical series were analysed by determining the ratio, proportions, chi-square and Student t-test and survival analysis. The study included 1002 patients with NSCLC treated at the UCRO, of whom 859 were males and 137 were females, and 0.6% missing data for gender. The average age of patients was 60.4 ± 9.0 y., min. of 19 y., max. of 85 y. Most of the patients were smokers- 86.9%. The dominant stage in NSCLC was stage IV, with 36.3%, followed by IIIA 17.5%, stages IIIB and IIB with 13.6% and so on. In the examined group of patients the most common subtype was 56.9% with planocellular, 28.2% with adenocarcinoma, large-cell with 7.7% and missing / no closer subtype 7.2%. Median survival from diagnosis to the last check-up/death was 6.2 m. 25% of patients with NSCLC from diagnosis to the last check-up/death died in the first 2.5 m and 25% survived more than 11.1 m. Median survival from treatment outset to the last check-up/death was 5.4 m. 25% of patients with NSCLC survived for two months from the outset of treatment to the last check-up/death and 25% survived for more than 10.8 m. In the course of the study we found that the median survival in 2009, 2010 and 2011 differed from the diagnosis to the last control/death. In 2009, median survival was 7.5 m and we registered a statistically significantly longer survival compared to 2010 - 6.1 m, and 2011 - 5.4 m. Similar data and conclusions were received in calculating the survival from therapy to the last check-up/death. Median survival in 2009 was 6.2 m and this is a statistically significant longer survival compared with 2010 (5.9 m) and 2011 (4.6 m). The results indicate that compared with international data patients with NSCLC had a shorter life of survival.We hope that this study will help to improve the future treatment of non-small-cell lung cancer patients through optimizing the treatment for every single patient, which will help in longer patient survival. Precise determination of these data provides for a proper selection of the best treatment option and optimized therapy for every patient." @default.
• W2186557382 created "2016-06-24" @default.
• W2186557382 creator A5017776900 @default.
• W2186557382 creator A5020956215 @default.
• W2186557382 creator A5028638355 @default.
• W2186557382 creator A5033074816 @default.
• W2186557382 date "2013-01-01" @default.
• W2186557382 modified "2023-09-30" @default.
• W2186557382 title "Epidemiological analysis of progression-free survival (PFS) and overall survival (OS) in non-small-cell lung cancer patients in Republic of Macedonia." @default.
• W2186557382 cites W121421619 @default.
• W2186557382 cites W1975621336 @default.
• W2186557382 cites W1985329793 @default.
• W2186557382 cites W2009671306 @default.
• W2186557382 cites W2011676048 @default.
• W2186557382 cites W2119805434 @default.
• W2186557382 cites W2121153361 @default.
• W2186557382 cites W2134654353 @default.
• W2186557382 cites W2140847299 @default.
• W2186557382 cites W2142850084 @default.
• W2186557382 cites W2165803850 @default.
• W2186557382 cites W3142144633 @default.
• W2186557382 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24566015" @default.
• W2186557382 hasPublicationYear "2013" @default.
• W2186557382 type Work @default.
• W2186557382 sameAs 2186557382 @default.
• W2186557382 citedByCount "2" @default.
• W2186557382 countsByYear W21865573822021 @default.
• W2186557382 countsByYear W21865573822023 @default.
• W2186557382 crossrefType "journal-article" @default.
• W2186557382 hasAuthorship W2186557382A5017776900 @default.
• W2186557382 hasAuthorship W2186557382A5020956215 @default.
• W2186557382 hasAuthorship W2186557382A5028638355 @default.
• W2186557382 hasAuthorship W2186557382A5033074816 @default.
• W2186557382 hasConcept C10515644 @default.
• W2186557382 hasConcept C107130276 @default.
• W2186557382 hasConcept C121608353 @default.
• W2186557382 hasConcept C126322002 @default.
• W2186557382 hasConcept C143998085 @default.
• W2186557382 hasConcept C2776256026 @default.
• W2186557382 hasConcept C2776283816 @default.
• W2186557382 hasConcept C71924100 @default.
• W2186557382 hasConceptScore W2186557382C10515644 @default.
• W2186557382 hasConceptScore W2186557382C107130276 @default.
• W2186557382 hasConceptScore W2186557382C121608353 @default.
• W2186557382 hasConceptScore W2186557382C126322002 @default.
• W2186557382 hasConceptScore W2186557382C143998085 @default.
• W2186557382 hasConceptScore W2186557382C2776256026 @default.
• W2186557382 hasConceptScore W2186557382C2776283816 @default.
• W2186557382 hasConceptScore W2186557382C71924100 @default.
• W2186557382 hasIssue "3" @default.
• W2186557382 hasLocation W21865573821 @default.
• W2186557382 hasOpenAccess W2186557382 @default.
• W2186557382 hasPrimaryLocation W21865573821 @default.
• W2186557382 hasRelatedWork W1955788743 @default.
• W2186557382 hasRelatedWork W2104219718 @default.
• W2186557382 hasRelatedWork W2414244068 @default.
• W2186557382 hasRelatedWork W2419775784 @default.
• W2186557382 hasRelatedWork W3015912822 @default.
• W2186557382 hasRelatedWork W3032022930 @default.
• W2186557382 hasRelatedWork W3114004622 @default.
• W2186557382 hasRelatedWork W3152764531 @default.
• W2186557382 hasRelatedWork W3178023238 @default.
• W2186557382 hasRelatedWork W4223523856 @default.
• W2186557382 hasVolume "34" @default.
• W2186557382 isParatext "false" @default.
• W2186557382 isRetracted "false" @default.
• W2186557382 magId "2186557382" @default.
• W2186557382 workType "article" @default.